We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA and EMA Take Action Against Zhejiang Huahai Over GMP Violations
FDA and EMA Take Action Against Zhejiang Huahai Over GMP Violations
The FDA placed valsartan manufacturer Zhejiang Huahai on an import alert and the EMA issued a noncompliance statement barring Europe’s drugmakers from using the company’s API in their blood pressure products.